EdiGene
is a China-based biotechnology company that develops and commercializes novel therapeutics for the treatment of genetic and cancer diseases... Read moreEdiGene
is a China-based biotechnology company that develops and commercializes novel therapeutics for the treatment of genetic and cancer diseases... Read more
News
May 02, 2023
Business Wire
Press Release: EdiGene : EdiGene to Unveil Promising Preclinical POC Data for LEAPER 2.0-based in vivo RNA Editing Therapies in NHP Model at the 26th Annual Meeting of ASGCT via Oral Presentation
Nov 18, 2022
Life Care News
EdiGene: EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent -thalassemia
Nov 10, 2022
BioPharma-Reporter
EdiGene: EdiGene Biotechnology moves into new R&D center in Massachusetts
May 03, 2022
AI Express
EdiGene: EdiGene to Present getools, a Data Analysis Software Toolkit for Advanced Analytics of DNA and RNA Editing Efficiency and Outcomes for Therapeutic Development at the ASGCT 25th Annual Meeting
Apr 13, 2022
Business Wire
Press Release: EdiGene : EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer
Mar 16, 2022
StreetInsider
Press Release: EdiGene : EdiGene Obtains Worldwide License from Boston Children's Hospital to Methods and Compositions for Increasing Fetal Hemoglobin Levels to Treat Hemoglobinopathies
Feb 11, 2022
Pharmabiz
EdiGene: EdiGene, Neukio ink R&D collaboration to develop nextgeneration immune cell therapies
Feb 10, 2022
MarketScreener
EdiGene: EdiGene Announces Publication by Company Scientific Founder in Nature Biotechnology of LEAPER 2.0, an Updated Version of the RNA Base Editing Technology Using Engineered Circular ADAR-recruiting RNAs
Feb 09, 2022
ChinaBio Today
EdiGene: EdiGene to Discover Stem Cell/Natural Killer CAR Therapy for Neukio
Feb 08, 2022
FirstWord Pharma
EdiGene: EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs
EdiGene Competitors
1
2
3
4
5
6
7
8
9
10